GlassScriptPhysician profile
Todd M Carpenter
NPI 1255629267
$1,675.87
in general payments reported to CMS, 2019-2025
14 companies · $742 in 2025
The $742 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $934 · 2025: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,618 · Education: $57.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,618.05 |
| Education | $57.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $786.01 | 2024-2025 | Tezspire, Airsupra, Fasenra |
| Regeneron Healthcare Solutions, INC. | $129.19 | 2024-2025 | Dupixent |
| Genzyme Corporation | $106.27 | 2025 | |
| Glaxosmithkline, LLC. | $104.76 | 2024-2025 | Nucala |
| Amgen INC. | $100.04 | 2024-2025 | Tezspire |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $98.00 | 2024 | Caplyta |
| Csl Behring | $72.05 | 2025 | Andembry |
| Biocryst US Sales Co., LLC | $71.86 | 2024-2025 | Orladeyo |
| Blueprint Medicines Corporation | $57.52 | 2024 | Ayvakit |
| Grifols USA, LLC | $44.23 | 2024-2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $33.88 | 2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $31.63 | 2024 | |
| Viatris Specialty LLC | $20.43 | 2025 | Yupelri |
| Baxter Healthcare | $20.00 | 2025 | Hillrom - Vest System Model 105 Home Care |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Carpenter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.